observed that in TNBC, pre‐existing TCR clones clonally expand in tumors responsive to ICIs and identified CXCL13+ T cells as potential tumor‐reactive T cells responsive to anti‐PD‐L1 blockade.[96] In lung cancer, Liu et al. The gene discussed is CXCL13; the disease is neoplasm.